Roger Stupp

Professor Stupp is an internationally recognized medical oncologist with a special focus on innovative cancer treatments. He is currently leading the Division of Neuro-Oncology, and serving as the Co-Director of the Malnati Brain Tumor Institute and Associate Director for the Lurie Comprehensive Cancer Center of Northwestern University in Chicago.

Former positions included Director of the Department of Oncology at the University Hospitall Zurich and numerous leadership positions in the Department of Oncology at the CHUV and the University of Lausanne. Dr. Stupp served in the Board of Directors of the European Organisation for Research and Treatment of Cancer (EORTC) from 2006 – 2022, from 2012 – 2017 as the President.

Dr. Stupp has been the lead investigator for numerous clinical trials from first-in-human phase 1 to pivotal phase 3 registration studies. In the brain tumor field, he is best known for his contributions of temozolomide (Temodal^®) and radiation in the first line treatment of brain tumors (the “stupp protocol”), and establishing MGMT as a predictive marker for benefit from alkylating agent chemotherapy in collaboration with Monika Hegi at the CHUV and University of Lausanne.

He was also the lead investigator establishing Tumor Treating Fields (Optune^®) as an innovative treatment modality, both are part of modern standard of care for patients with glioblastoma. Ongoing research is focusing on overcoming the protective blood-brain barrier using innovative technologies that facilitate novel medicines (including immunotherapy) to reach tumor in higher concentrations.